Prenatal Interventions for Congenital Diaphragmatic Hernia: A Systematic Review
Abdulaziz S Altala1, Mohayad Ahmed2, Ahmed O AlGhamdi3
1Department of Basic Medical Sciences, College of Medicine, Dar Al Uloom University, Riyadh, SAU.
Insights
Fetoscopic endoluminal tracheal occlusion (FETO) improves survival for severe congenital diaphragmatic hernia (CDH) but increases neonatal and maternal morbidity. Careful patient selection is crucial for optimal outcomes in CDH management.
Area of Science:
- Perinatal Medicine
- Fetal Surgery
- Neonatal Critical Care
Background:
- Congenital diaphragmatic hernia (CDH) presents a significant threat to newborns, often leading to high mortality and morbidity despite advanced care.
- Fetoscopic endoluminal tracheal occlusion (FETO) is an emerging prenatal intervention aimed at improving lung development and postnatal survival in fetuses with severe CDH.
- The comparative efficacy of FETO versus expectant management, particularly concerning maternal and neonatal outcomes, remains a subject of ongoing debate and investigation.
Purpose of the Study:
- To systematically compare the neonatal and maternal outcomes of fetoscopic endoluminal tracheal occlusion (FETO) versus expectant management in cases of severe or moderate congenital diaphragmatic hernia (CDH).
- To evaluate the impact of FETO on survival rates, neonatal morbidity, and maternal complications.
- To provide evidence-based insights for optimizing patient selection and clinical decision-making in CDH management.
Main Methods:
- A PICO-based systematic review was conducted, including randomized controlled trials, cohort studies, and retrospective analyses.
- Literature searches were performed across PubMed, OpenAlex, and CENTRAL, yielding 669 records, with 40 papers meeting PRISMA eligibility criteria.
- Data extraction and statistical analyses were performed using RStudio to assess survival rates, morbidity patterns, and maternal risk factors.
Main Results:
- Pooled analyses suggest FETO may improve survival in severe CDH cases with liver herniation compared to expectant management, though survival trends vary across studies.
- FETO is associated with increased neonatal morbidity, including higher incidences of pulmonary hypertension, prolonged ventilatory support, and gastrointestinal complications.
- FETO significantly increases the risk of preterm premature rupture of membranes (PPROM) and preterm delivery, leading to earlier gestational age at birth and potential NICU admission.
Conclusions:
- While FETO can improve survival in severe CDH, it is linked to increased neonatal and maternal morbidity, including PPROM and preterm birth.
- Precise patient selection is paramount to maximize the benefits of FETO while minimizing associated risks.
- FETO should be reserved for severe CDH cases where survival benefits clearly outweigh the potential complications, necessitating further research into standardized procedures and risk reduction strategies.
Abstract:
Life-threatening congenital diaphragmatic hernia (CDH) is a defect with subsequent herniation of abdominal organs. Herniation of abdominal organs into the thoracic cavity causes pulmonary hypoplasia and hypertension. Despite improved baby critical care and surgical therapy, severe CDH has high mortality and morbidity rates. The prenatal intervention of fetoscopic endoluminal tracheal occlusion (FETO) has become popular for improving postnatal survival and lung development. However, its efficacy in reducing maternal risks, morbidity, and improving newborn survival is still debated. This systematic study compares FETO with expectant management of mothers on neonatal and maternal outcomes. A PICO-based systematic review was conducted. The study included fetuses with severe or moderate CDH. The intervention group had FETO, while the control group had expectant management with postnatal surgery. Neonatal survival, morbidity, and maternal problems were evaluated. A complete PubMed, OpenAlex, and CENTRAL search yielded 669 records. Forty papers met Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) eligibility criteria after deleting 154 duplicates, screening 515 abstracts, and analyzing 102 full-text articles. RCTs, cohort studies, and retrospective analyses were conducted. The data were extracted after title and abstract screening, followed by full-text screening using inclusion and exclusion criteria. Statistical analyses were then performed using RStudio (Posit PBC, Boston, MA, USA) to assess morbidity patterns, maternal risk factors, and pooled survival rates. Pooled analyses suggest that FETO may be associated with improved survival in severe CDH cases with liver herniation compared to expectant management. Some studies report noticeably higher survival rates with FETO, though others have shown the opposite trend, possibly reflecting differences in patient selection criteria. FETO has also been associated with higher incidences of pulmonary hypertension, prolonged ventilatory support, and increased risk of gastrointestinal complications such as feeding difficulties, gastroesophageal reflux, and reherniation. The impact of FETO on extracorporeal membrane oxygenation requirements appears inconsistent across studies, with some indicating a reduced need and others reporting similar rates regardless of intervention. A notable concern with FETO is its association with increased risks of preterm premature rupture of membranes (PPROM) and preterm delivery. PPROM has been reported in nearly half of FETO cases, compared to lower rates in expectant management. Correspondingly, gestational age at delivery tends to be earlier in FETO pregnancies, potentially contributing to lower birth weights and higher rates of neonatal intensive care unit admission. Serious maternal complications, such as hemorrhage, sepsis, or organ injury, are infrequently reported. FETO improves survival in severe CDH cases; however, this systematic analysis demonstrates that treatment increases neonatal morbidity and maternal morbidity. The findings highlight the importance of precise patient selection to maximize benefits and minimize risks. Clinically, FETO should be reserved for severe CDH cases in which the survival benefits outweigh the problems. Future research should focus on standardizing FETO procedures, enhancing postnatal care, and investigating other therapies to reduce PPROM and preterm birth risk.


